How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,342 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. Myocardial Rupture (Treatment)

of free-wall rupture while patients are being transferred to the OR. Previous Next: Surgical Repair In most patients, immediate surgery is necessary and should not be delayed by attempts to stabilize the patient medically. Papillary muscle rupture is generally treated with mitral valve replacement. Free-wall rupture is treated by resecting the infarcted area and closing the rupture zone with Teflon or Dacron patches or by using of biologic glues. Successful off-pump surgery (without the use (...) , Lick S, Uretsky BF. Contained myocardial rupture: a variant linking complete and incomplete rupture. Heart . 2005 Feb. 91(2):e13. . Okino S, Nishiyama K, Ando K, Nobuyoshi M. Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction undergoing percutaneous coronary intervention. J Interv Cardiol . 2005 Jun. 18(3):167-72. . Kumar S, Kaushik S, Nautiyal A, et al. Cardiac rupture in takotsubo cardiomyopathy: a systematic review. Clin Cardiol . 2011 Nov. 34(11

2014 eMedicine.com

222. Myocardial Abscess (Treatment)

Abscess Treatment & Management Updated: Nov 07, 2018 Author: Vibhuti N Singh, MD, MPH, FACC, FSCAI; Chief Editor: Mark R Wallace, MD, FACP, FIDSA Share Email Print Feedback Close Sections Sections Myocardial Abscess Treatment Medical Care Medical treatment includes the following: Antibiotics Agents for stabilization of hemodynamic status Supportive treatment includes the following: Fluid and electrolyte balance Nutritional support Next: Surgical Care Once the diagnosis of myocardial abscess is made (...) Anticoagulation therapy, in case of metallic prosthetic valve replacement Continuing antibiotic therapy Diuretic use with CHF Antiarrhythmic therapy for postoperative arrhythmias Aggressive antibiotic prophylaxis prior to minor surgeries Previous Next: Further Inpatient Care Aggressive postoperative supportive therapy in patients with myocardial abscess includes the following: Agents for stabilization of hemodynamics Fluid and electrolyte balance Nutrition (parenteral or enteral) Continuation of antibiotic

2014 eMedicine.com

223. Myocardial Ischemia (Treatment)

. One study demonstrated a significant reduction of symptomatic myocardial ischemia in patients with unstable angina or non–Q-wave infarction with the administration of a statin during the early acute phase. In a study of 10,001 patients with stable coronary artery disease, an aggressive cholesterol-lowering approach with atorvastatin 80 mg daily (mean cholesterol level of 77 mg/dL) compared to a less-aggressive approach with atorvastatin 10 mg daily (mean cholesterol level of 101 mg/dL) resulted (...) in a 2.2% absolute reduction and a 22% relative reduction in the occurrence of a first major cardiovascular event (defined as death from coronary heart disease; nonfatal, non–procedure-related myocardial infarction; resuscitation from cardiac arrest; or fatal or nonfatal stroke). [ ] This occurred with a greater incidence of elevated aminotransferase levels with the aggressive cholesterol-lowering approach (1.2% vs 0.2%, p < 0.001). Some triglyceride-rich lipoproteins, including partially degraded very

2014 eMedicine.com

224. Myocardial Rupture (Follow-up)

of free-wall rupture while patients are being transferred to the OR. Previous Next: Surgical Repair In most patients, immediate surgery is necessary and should not be delayed by attempts to stabilize the patient medically. Papillary muscle rupture is generally treated with mitral valve replacement. Free-wall rupture is treated by resecting the infarcted area and closing the rupture zone with Teflon or Dacron patches or by using of biologic glues. Successful off-pump surgery (without the use (...) , Lick S, Uretsky BF. Contained myocardial rupture: a variant linking complete and incomplete rupture. Heart . 2005 Feb. 91(2):e13. . Okino S, Nishiyama K, Ando K, Nobuyoshi M. Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction undergoing percutaneous coronary intervention. J Interv Cardiol . 2005 Jun. 18(3):167-72. . Kumar S, Kaushik S, Nautiyal A, et al. Cardiac rupture in takotsubo cardiomyopathy: a systematic review. Clin Cardiol . 2011 Nov. 34(11

2014 eMedicine.com

225. Myocardial Abscess (Follow-up)

Abscess Treatment & Management Updated: Nov 07, 2018 Author: Vibhuti N Singh, MD, MPH, FACC, FSCAI; Chief Editor: Mark R Wallace, MD, FACP, FIDSA Share Email Print Feedback Close Sections Sections Myocardial Abscess Treatment Medical Care Medical treatment includes the following: Antibiotics Agents for stabilization of hemodynamic status Supportive treatment includes the following: Fluid and electrolyte balance Nutritional support Next: Surgical Care Once the diagnosis of myocardial abscess is made (...) Anticoagulation therapy, in case of metallic prosthetic valve replacement Continuing antibiotic therapy Diuretic use with CHF Antiarrhythmic therapy for postoperative arrhythmias Aggressive antibiotic prophylaxis prior to minor surgeries Previous Next: Further Inpatient Care Aggressive postoperative supportive therapy in patients with myocardial abscess includes the following: Agents for stabilization of hemodynamics Fluid and electrolyte balance Nutrition (parenteral or enteral) Continuation of antibiotic

2014 eMedicine.com

226. Myocardial Ischemia (Follow-up)

. One study demonstrated a significant reduction of symptomatic myocardial ischemia in patients with unstable angina or non–Q-wave infarction with the administration of a statin during the early acute phase. In a study of 10,001 patients with stable coronary artery disease, an aggressive cholesterol-lowering approach with atorvastatin 80 mg daily (mean cholesterol level of 77 mg/dL) compared to a less-aggressive approach with atorvastatin 10 mg daily (mean cholesterol level of 101 mg/dL) resulted (...) in a 2.2% absolute reduction and a 22% relative reduction in the occurrence of a first major cardiovascular event (defined as death from coronary heart disease; nonfatal, non–procedure-related myocardial infarction; resuscitation from cardiac arrest; or fatal or nonfatal stroke). [ ] This occurred with a greater incidence of elevated aminotransferase levels with the aggressive cholesterol-lowering approach (1.2% vs 0.2%, p < 0.001). Some triglyceride-rich lipoproteins, including partially degraded very

2014 eMedicine.com

227. A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. (Abstract)

I6WP63U32H Acenocoumarol AIM IM Acenocoumarol therapeutic use Blood Coagulation drug effects Blood Coagulation Tests Coronary Disease drug therapy Coumarins therapeutic use Female Humans Male Middle Aged Myocardial Infarction prevention & control 1969 10 1 1969 10 1 0 1 1969 10 1 0 0 ppublish 5378105 (...) A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. 5378105 1970 05 04 2013 11 21 0001-6101 186 4 1969 Oct Acta medica Scandinavica Acta Med Scand A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. 283-8 Breed W P WP van Hooff J P JP Haanen C C eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Sweden Acta Med Scand 0370330 0001-6101 0 Coumarins

1970 Acta Medica Scandinavica Controlled trial quality: uncertain

228. Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.

imaging study was processed and read independently by 3 technologists. Mean heart/mediastinum (H/M) ratio difference (with 95% confidence interval [CI]) was used as the measure of test stability. Secondary Outcome Measures : To Assess the Test-retest Reproducibility of Iobenguane I 123 Injection Myocardial Uptake on Planar Imaging at 15 Minutes Following Administration of AdreView (Iobenguane I 123 Injection) [ Time Frame: 15 minutes post administration of 2 dosing within an interval of 5 to 14 days (...) to enrollment into the study. The participant had received defibrillation either external or via an implantable cardioverter defibrillator (ICD), anti-tachycardia pacing, or cardioversion to treat an arrhythmic event in the previous 90 days. The participant had a cardiac revascularization, insertion of an ICD, or acute myocardial infarction within 30 days before study entry. The participant used any of the following medications: Amitriptyline and derivatives, imipramine and derivatives, other

2013 Clinical Trials

229. Desipramine Pretreatment Improves Sympathetic Remodeling and Ventricular Fibrillation Threshold after Myocardial Ischemia (Full text)

Desipramine Pretreatment Improves Sympathetic Remodeling and Ventricular Fibrillation Threshold after Myocardial Ischemia Abnormal increase in sympathetic nerve sprouting was responsible for the ventricular arrhythmogenesis after myocardial infarction. This study investigated whether the norepinephrine transporter inhibitor, desipramine, can modulate sympathetic remodeling and ventricular fibrillation threshold (VFT) after myocardial ischemia-reperfusion. Rats were administered desipramine (0.8 (...)  mg/kg, i.v.) before or after myocardial ischemia. VFT, infarct size, tyrosine hydroxylase (TH) and growth-associated protein 43 (GAP43)-positive nerve fibers were measured after one week. The VFT of preischemic treatment group was 11.0 ± 2.65 V and significantly higher than that of control ischemic group (7.2 ± 1.30 V, P < 0.05). Infarct size in the preischemic treatment group (23.3 ± 2.4%) was significantly lower than that in the control ischemic group (30.8 ± 1.3%, P < 0.05) and the delayed

2012 Journal of Biomedicine and Biotechnology PubMed abstract

230. Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia

, as documented by echocardiography Planned staged treatment of CAD or other intervention on the heart Platelet count < 100,000/mm3 WBC < 2,000/mm3 TIA or stroke within 90 days prior to randomization ICD shock within 30 days of randomization Any condition requiring immunosuppressive medication A high-risk acute coronary syndrome (ACS) or a myocardial infarction within 60 days prior to randomization Revascularization within 60 days prior to randomization Inability to walk on a treadmill except for class IV (...) Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2012 Clinical Trials

231. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV) (Abstract)

Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV) This study evaluated the effectiveness and safety of beta-blockers and statins for the prevention of perioperative cardiovascular events in intermediate-risk patients undergoing noncardiovascular surgery.Beta-blockers and statins reduce perioperative cardiac events in high-risk (...) patients undergoing vascular surgery by restoring the myocardial oxygen supply/demand balance and/or stabilizing coronary plaques. However, their effects in intermediate-risk patients remained ill-defined.In this randomized open-label 2 x 2 factorial design trial 1066 intermediate cardiac risk patients were assigned to bisoprolol, fluvastatin, combination treatment, or control therapy before surgery (median: 34 days). Intermediate risk was defined by an estimated risk of perioperative cardiac death

2009 EvidenceUpdates Controlled trial quality: predicted high

232. Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI)

Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI) Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01065103 Recruitment Status : Completed First Posted : February 9, 2010 Last Update

2010 Clinical Trials

233. Extracorporeal Membrane Oxygenation for Cardiac Indications in Adults

, such as acute myocardial infarction [heart attack] or myocarditis [inflammation of the heart muscle]), valvular dysfunction (damage to any of the four valves that control the flow of blood between the heart’s chambers), or conduction system dysfunction (problems with how electrical impulses travel through the heart and ensure it beats properly). 2 Cardiac arrest and cardiogenic shock are medical emergencies and require immediate treatment. Clinical Need and Target Population Worldwide, the annual incidence (...) to be younger, healthier, and with better prognostic features (characteristics of a patient that can be used to estimate the chance of recovery). Patients who receive timely CPR from bystanders have a greater chance of surviving out-of-hospital cardiac arrest than those who do not. 3 Acute myocardial infarction accounts for about 80% of cardiogenic shock cases. 4 In people with a type of heart attack known as ST-segment elevation myocardial infarction (in which some heart muscle dies due to a block in blood

2020 Health Quality Ontario

235. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic (Full text)

of this equipment; All patients entering the catheterization laboratory should wear a surgical mask. 5.2.5.1. ST-Segment Elevation Myocardial Infarction Because there is no time to wait for nasopharyngeal swab result, the procedure should be performed in a dedicated catheterization laboratory if available and patients should be triaged according to . In regions with high rates of community transmission, it is reasonable to regard all patients as possible positive and protected accordingly ( ) 5.2.5.2. Non-ST (...) -Segment Elevation Myocardial Infarction – Acute Coronary Syndrome Very high-risk non-ST-segment elevation ( )- should follow the ST-segment elevation myocardial infarction ( ) pathway and protected accordingly; Others should undergo a nasopharyngeal swab immediately after admission ( ). When there are two negative results within 48 hours and absence of suspicious symptoms of virus infection, coronary angiography and eventual percutaneous coronary intervention ( ) may be performed in a catheterization

2020 European Society of Cardiology PubMed abstract

236. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. (Full text)

Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. To investigate growth differentiation factor (GDF)-15 at hospital discharge for assessment of the risk of death, recurrent myocardial infarction (MI), and congestive heart failure, and to determination of whether these risks can be modified by statins.GDF-15 is a transforming growth factor-β-related cytokine induced in response to tissue injury

2011 Arteriosclerosis, thrombosis, and vascular biology Controlled trial quality: uncertain PubMed abstract

237. HFR A-equilibrium on Cardiovascular Stability

less than 2 ml/min/1.73 m2 native fistula or central venous catheter with blood flow rate greater than 250 ml/min Exclusion Criteria: Life expectancy less than 1 year solid active neoplasm pregnancy major event in the previous 3 months (ictus, myocardial infarction, cachexia) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor (...) HFR A-equilibrium on Cardiovascular Stability HFR A-equilibrium on Cardiovascular Stability - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. HFR A-equilibrium on Cardiovascular Stability (AIMS) The safety

2011 Clinical Trials

238. A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery; rationale and design of DECREASE-XIII. (Full text)

of heart rate outside the target window during infusion of the study drug. Secondary outcome measures will be the efficacy parameters of occurrence of cardiac ischaemia, troponin T release, myocardial infarction and cardiac death within 30 days after surgery and safety parameters such as the occurrence of stroke and hypotension.This study will provide data on the efficacy of esmolol titration in chronic beta-blocker users for tight heart-rate control and reduction of ischaemia in patients undergoing (...) A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery; rationale and design of DECREASE-XIII. This article describes the rationale and design of the DECREASE-XIII trial, which aims to evaluate the potential of esmolol infusion, an ultra-short-acting beta-blocker, during surgery as an add-on to chronic low-dose beta-blocker therapy to maintain perioperative haemodynamic stability during major vascular surgery.A double-blind, placebo

2011 European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery Controlled trial quality: predicted high PubMed abstract

239. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis (Full text)

-357 Furthermore, unlike the previous studies, patients with a creatinine clearance of 60 mL or more per minute were enrolled. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke. The primary efficacy outcomes were MACE and a composite of cardiovascular death or HHF. The rates of MACE were not statistically different (HR, 0.93; 95% CI, 0.84-1.03; P = 0.17), however, the composite (...) , resulting in organ failure. Merlini G. Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349 : 583-596 CA is a form of infiltrative cardiomyopathy that develops when amyloid deposits infiltrate myocardial tissue. This infiltrative process results in progressive ventricular stiffness, wall thickening, and diastolic filling abnormalities, which typically manifest as HFpEF and restrictive physiology. Falk R.H. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005; 112

2020 Canadian Cardiovascular Society PubMed abstract

240. Polyvalent immunoglobulins – Part 1: A rapid review

with a focus on AEs from general search The SR by Ammann et al. (AMSTAR 8/11), focused on thromboembolic events (TEEs). The SR focused only on RCTs with a low RoB, and included 31 studies overall, on 4129 patients 37 . The median length of follow-up was 9 months and the median of the trial mean ages was 47 years (ranging from 29 to 70 years). The main outcome of interest was the rate of serious TEEs (i.e. acute myocardial infarction; ischemic stroke or venous thromboembolism). Arterial and venous TEEs were (...) LoS Length of Stay MA Meta-Analysis MFAs Myocardial Function Abnormalities MG Myasthenia Gravis MM Multiple Myeloma MMN Multifocal motor neuropathy MMRC Modified Medical Research Council MORSE report Monitoring Of Reimbursement Significant Expenses - report NBA National Blood Authority (Australia) NHS England National Health Service England NIHDI-RIZIV-INAMI PE National Institute of Health and Disability Insurance Plasma Exchange PID PP Primary Immunodeficiency Per protocol PTP Post transfusion

2020 Belgian Health Care Knowledge Centre

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>